IDXX logo

IDEXX LABORATORIES INC

IDXXNASDAQ
πŸ† #307 by market capEarnings Nov 2 Β· PreUS Equity
$563.11β€”
Last available close Β· quote unavailable
πŸ””
Track IDXX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 0.6%
14dβ–² 2.9%
30dβ–² 5.5%
ytdβ–Ό 16.8%
1yβ–Ό 10.3%
🏦Market Cap
$44.35B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
10.4%
Healthy
πŸ“ŠGross Margin
62.5%
High
πŸ’΅FCF Margin
27.5%
Strong
βš–οΈP/S Ratio
9.7x
Elevated
Otter Score
80
Strong

Trading Snapshot

Day Range
β€”
52-Week Range
$500.61 – $769.98
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
78.8M
Next Earnings
2026-11-02

Fundamentals Snapshot

Annual Revenue
$4.30B
Last Q Revenue
$1.22B
P/E Ratio
39.5
P/S Ratio
9.7x
EPS (TTM)
$14.23
Dividend Yield
0.00%
Dilution (1yr)
βˆ’2.3%
IDXX logo

IDEXX LABORATORIES INC

IDXX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.3Bβ–² +10.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.8%β–² +1.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.4Bβ–² +20.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.1Bβ–² +32.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
80.7Mβ–Ό βˆ’2.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$897Mβ–Ό βˆ’$198M YoY
StockOtter Β· stockotter.space

About IDEXX LABORATORIES INC

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100

Analyst Ratings

β“˜
Consensus
Buy
21 analysts
Strong Buy7
Buy7
Hold7
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.